CD274 and neoplasm: In current clinical practice, various biomarkers such as PD-L1 expression, tumor mutational burden (TMB), MSI, microbiome composition, hypoxia levels, IFN-γ levels, and extracellular matrix characteristics are utilized as prognostic indicators to predict the clinical response to immunotherapy among patients receiving ICIs [162].